Literature DB >> 7520166

Establishment and characterization of a malignant melanoma cell line (YP-MEL) derived from a patient with neurocutaneous melanosis.

Y Nagashima1, Y Miyagi, I Aoki, T Funabiki, K Ikuta, M Umeda, Y Kuchino, K Misugi.   

Abstract

A cell line, YP-MEL, was established from an intracranial malignant melanoma occurring in a neurocutaneous melanosis (NCMsis) patient. The established cell line was successfully cultured in serum-free medium with a doubling time of 41 h. The cells were refractile and small in size, with occasional pigmented giant cells. Histochemical and immunohistochemical features were compatible with common malignant melanoma and its cell line. Chromosome analysis revealed many supernumerary chromosomes and marker chromosomes including double minutes (DMs). When transplanted into nude mice, YP-MEL formed tumors histologically consistent with the original tumor. Addition of sera to the medium caused cellular spreading and elongation of cytoplasmic processes with an increase of melanin contents and tyrosinase activity. Because there was no melanoma cell line derived from a NCMsis patient, YP-MEL might be a beneficial tool for study on NCMsis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520166     DOI: 10.1016/S0344-0338(11)80709-0

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.

Authors:  Dipanjan Basu; Cláudia M Salgado; Bruce S Bauer; Donald Johnson; Veronica Rundell; Marina Nikiforova; Yasmin Khakoo; Lorelei J Gunwaldt; Ashok Panigrahy; Miguel Reyes-Múgica
Journal:  Neuro Oncol       Date:  2015-09-09       Impact factor: 12.300

3.  NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.

Authors:  Giulia Angelino; Maria Debora De Pasquale; Luigi De Sio; Annalisa Serra; Luca Massimi; Rita De Vito; Antonio Marrazzo; Laura Lancella; Andrea Carai; Manila Antonelli; Felice Giangaspero; Marco Gessi; Laura Menchini; Laura Scarciolla; Daniela Longo; Angela Mastronuzzi
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

4.  Lin28A/let-7 oncogenic circuit is a potential therapeutic target in neurocutaneous melanosis-associated CNS tumors in children.

Authors:  Mohit Jain; Son Tran; Satbir Thakur; Yoji Nagashima; Ronald Anderson; Aru Narendran
Journal:  Neurooncol Adv       Date:  2020-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.